2 Scariest Dividend Stocks in Health Care
The yields look great, but these 2 health-care dividend stocks could be the scariest ones around in the near future.
Racing Toward the Next Hepatitis C Drug Approval
Johnson & Johnson jumps ahead of Gilead Sciences in the race to bring next-generation hepatitis C drugs to market.
3 Investment Strategy Lessons From Vertex's Success
Can you develop an investment strategy based on a biotech success story? Here are 3 lessons that show how it can be done.